Safinamide
Brand: Xadago (global)
Neurological
MAO-B inhibitor (reversible, adjunct to levodopa)
Pharmacokinetics
| Half-life | 22 hours |
| Tmax | 2 h |
| Bioavailability | 95 % (approx) |
| Protein Binding | 92 % |
| Volume of Distribution | 2 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Linear pharmacokinetics; high oral bioavailability; primarily metabolized via amidase hydrolysis and oxidation; excreted in urine (~76%). |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Dyskinesia, insomnia, nausea, hypertension, visual disturbances
Contraindications:
Severe hepatic impairment; concomitant use with opioids, SSRIs, or SNRIs (risk of serotonin syndrome)
Precautions:
Avoid abrupt withdrawal; monitor BP; adjust dose in moderate hepatic impairment